JP2008514642A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008514642A5 JP2008514642A5 JP2007533762A JP2007533762A JP2008514642A5 JP 2008514642 A5 JP2008514642 A5 JP 2008514642A5 JP 2007533762 A JP2007533762 A JP 2007533762A JP 2007533762 A JP2007533762 A JP 2007533762A JP 2008514642 A5 JP2008514642 A5 JP 2008514642A5
- Authority
- JP
- Japan
- Prior art keywords
- crystalline form
- methylpropyloxy
- methylpiperidin
- fluorobenzyl
- phenylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61401404P | 2004-09-27 | 2004-09-27 | |
| US60/614,014 | 2004-09-27 | ||
| PCT/US2005/034813 WO2006037043A1 (en) | 2004-09-27 | 2005-09-26 | Synthesis of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008514642A JP2008514642A (ja) | 2008-05-08 |
| JP2008514642A5 true JP2008514642A5 (enExample) | 2011-08-04 |
| JP4996467B2 JP4996467B2 (ja) | 2012-08-08 |
Family
ID=35539440
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007533762A Expired - Lifetime JP4996467B2 (ja) | 2004-09-27 | 2005-09-26 | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミド、並びにその酒石酸塩及び結晶形態の合成 |
| JP2007533699A Expired - Lifetime JP5154227B2 (ja) | 2004-09-27 | 2005-09-26 | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドの塩及びその調製 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007533699A Expired - Lifetime JP5154227B2 (ja) | 2004-09-27 | 2005-09-26 | Ｎ−（４−フルオロベンジル）−ｎ−（１−メチルピペリジン−４−イル）−ｎ’−（４−（２−メチルプロピルオキシ）フェニルメチル）カルバミドの塩及びその調製 |
Country Status (17)
| Country | Link |
|---|---|
| US (6) | US7868176B2 (enExample) |
| EP (3) | EP2289879B1 (enExample) |
| JP (2) | JP4996467B2 (enExample) |
| KR (2) | KR20070083800A (enExample) |
| CN (3) | CN101031548B (enExample) |
| AU (2) | AU2005289635A1 (enExample) |
| BR (1) | BRPI0516063A (enExample) |
| CA (2) | CA2580136C (enExample) |
| DK (1) | DK1794126T3 (enExample) |
| ES (2) | ES2412207T3 (enExample) |
| MX (2) | MX2007003433A (enExample) |
| NZ (1) | NZ553702A (enExample) |
| PL (2) | PL1794126T3 (enExample) |
| RU (2) | RU2387643C2 (enExample) |
| SG (2) | SG161221A1 (enExample) |
| WO (2) | WO2006037043A1 (enExample) |
| ZA (3) | ZA200702349B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100879647B1 (ko) * | 2000-03-06 | 2009-01-20 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
| NZ533567A (en) * | 2001-12-28 | 2007-06-29 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
| JP2005533813A (ja) * | 2002-06-24 | 2005-11-10 | アカディア ファーマシューティカルズ，インコーポレーテッド | セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体 |
| US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| MY139563A (en) * | 2002-09-04 | 2009-10-30 | Bristol Myers Squibb Co | Heterocyclic aromatic compounds useful as growth hormone secretagogues |
| ATE407117T1 (de) | 2003-01-16 | 2008-09-15 | Acadia Pharm Inc | Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen |
| US7820695B2 (en) * | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US20050261278A1 (en) * | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| CN101031548B (zh) | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
| US7790899B2 (en) * | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
| WO2007124136A1 (en) * | 2006-04-19 | 2007-11-01 | Acadia Pharmaceuticals, Inc. | Use of 4-amino-piperidines for treating sleep disorders |
| CA2652300A1 (en) * | 2006-05-15 | 2007-11-22 | Acadia Pharmaceuticals Inc. | Pharmaceutical formulations of pimavanserin |
| WO2008116024A2 (en) | 2007-03-19 | 2008-09-25 | Acadia Pharmaceuticals Inc. | Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics |
| US20080280886A1 (en) * | 2007-05-08 | 2008-11-13 | Auspex Pharmaceuticals, Inc. | Substituted ureas |
| WO2008144665A1 (en) * | 2007-05-18 | 2008-11-27 | Acadia Pharmaceuticals Inc. | Use of pimavanserin in the treatment of parkinson and symptoms thereof |
| NO2200610T3 (enExample) * | 2007-09-21 | 2018-06-09 | ||
| WO2009039461A2 (en) * | 2007-09-21 | 2009-03-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| EA020090B1 (ru) * | 2008-06-30 | 2014-08-29 | Янссен Фармацевтика Нв | Способ получения и рекристаллизации кристаллического гемитартрата бензоимидазол-2-илпиримидинового производного |
| US9737531B2 (en) | 2012-07-12 | 2017-08-22 | Glytech, Llc | Composition and method for treatment of depression and psychosis in humans |
| AR091507A1 (es) * | 2012-06-21 | 2015-02-11 | Intra Cellular Therapies Inc | SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA |
| US9446037B2 (en) | 2012-11-27 | 2016-09-20 | Acadia Pharmaceuticals Inc. | Methods for the treatment of parkinson's disease psychosis using pimavanserin |
| EP3010509B1 (en) * | 2013-06-21 | 2021-07-28 | Intra-Cellular Therapies, Inc. | Free base crystals |
| JP2015117192A (ja) * | 2013-12-17 | 2015-06-25 | 東和薬品株式会社 | シロドシンγ型結晶及びその製造方法 |
| CN104961671B (zh) * | 2014-09-05 | 2018-01-02 | 苏州晶云药物科技有限公司 | N‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑(2‑甲基丙氧基)‑苯基甲基)脲半酒石酸盐的晶型及其制备方法 |
| EP3271018B1 (en) | 2015-03-02 | 2020-12-23 | Pliva Hrvatska D.O.O. | Processes and intermediates for the preparation of pimavanserin |
| CN104961672B (zh) * | 2015-05-20 | 2017-10-20 | 沈阳药科大学 | 一种n‑(4‑氟苄基)‑n‑(1‑甲基哌啶‑4‑基)‑n’‑(4‑异丁氧基苄基)脲的酒石酸盐的合成方法 |
| CN104844502B (zh) * | 2015-06-05 | 2018-07-31 | 齐鲁师范学院 | 一种匹莫范色林的制备方法 |
| CN107848972B (zh) * | 2015-07-20 | 2021-06-18 | 阿卡蒂亚药品公司 | 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法 |
| CZ2015601A3 (cs) | 2015-09-02 | 2017-03-15 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jejích deuterovaných analog neobsahujících dimerické nečistoty |
| CN105111135A (zh) * | 2015-09-09 | 2015-12-02 | 安徽省逸欣铭医药科技有限公司 | 取代的尿素衍生物制备方法 |
| CZ2015688A3 (cs) | 2015-10-02 | 2017-04-12 | Zentiva, K.S. | Způsob výroby 1-(4-fluorobenzyl)-3-(4-isobutoxybenzyl)-1-(1-methylpiperidin-4-yl)močoviny a jeho deuterovaných analogů |
| CN105153016B (zh) * | 2015-10-12 | 2017-10-03 | 北京诺康达医药科技有限公司 | 一种匹莫范色林的制备方法 |
| CN106588753B (zh) * | 2015-10-19 | 2021-07-09 | 重庆医药工业研究院有限责任公司 | 一种制备匹马色林的方法 |
| CN106699637A (zh) * | 2015-11-17 | 2017-05-24 | 重庆医药工业研究院有限责任公司 | 一种匹马色林单酒石酸盐晶型及其制备方法 |
| CN105924381B (zh) * | 2015-12-18 | 2019-04-16 | 重庆两江药物研发中心有限公司 | 一种哌马色林晶型c的制备方法 |
| CN105481757A (zh) * | 2015-12-25 | 2016-04-13 | 北京康立生医药技术开发有限公司 | 一种哌马色林的制备方法 |
| CN105523993A (zh) * | 2015-12-28 | 2016-04-27 | 重庆两江药物研发中心有限公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲酒石酸盐晶型c及制备应用 |
| CN107021917B (zh) * | 2016-02-02 | 2020-08-04 | 江苏恩华药业股份有限公司 | 哌马色林半酒石酸盐的新晶型及其制备方法 |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| EP3436010B1 (en) | 2016-03-29 | 2021-03-10 | Acadia Pharmaceuticals Inc. | 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques |
| CN105820110B (zh) * | 2016-05-09 | 2018-07-24 | 杭州科巢生物科技有限公司 | 匹莫范色林合成方法 |
| WO2018049836A1 (zh) | 2016-05-19 | 2018-03-22 | 上海诚妙医药科技有限公司 | 匹莫范色林酒石酸盐的新晶型及其制备方法和用途 |
| CN105859608B (zh) * | 2016-05-27 | 2018-12-28 | 成都百裕制药股份有限公司 | 一种制备哌马色林半酒石酸盐晶型b的方法 |
| HU231097B1 (hu) * | 2016-07-08 | 2020-08-28 | Egis Gyógyszergyár Zrt. | Gyógyászati készítmény előállítására alkalmazható pimavanserin sók |
| WO2018054359A1 (zh) * | 2016-09-23 | 2018-03-29 | 上海医药集团股份有限公司 | 一种喹唑啉衍生物的盐、其制备方法及应用 |
| EP3558311A1 (en) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin alone or in combination for use in the treatment of alzheimer's disease psychosis |
| US20180208556A1 (en) | 2017-01-20 | 2018-07-26 | Sci Pharmtech, Inc. | Method for Preparing Pimavanserin |
| CN106916098A (zh) * | 2017-03-07 | 2017-07-04 | 江苏艾立康药业股份有限公司 | 一种哌马色林单酒石酸盐半水合物及制备方法 |
| WO2018200977A1 (en) | 2017-04-28 | 2018-11-01 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| KR102608479B1 (ko) | 2017-05-25 | 2023-12-01 | 글리테크 엘엘씨. | Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법 |
| CN107216271B (zh) * | 2017-06-02 | 2018-11-13 | 沈阳药科大学 | 酒石酸匹莫范色林杂质及其制备方法 |
| CA3067162A1 (en) | 2017-06-12 | 2018-12-20 | Glytech Llc. | Composition and method for treatment or depression and psychosis in humans |
| WO2019040107A1 (en) * | 2017-08-21 | 2019-02-28 | Acadia Pharmaceuticals Inc. | COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES |
| US11440884B2 (en) | 2017-08-21 | 2022-09-13 | Acadia Pharmaceuticals Inc. | Compounds, salts thereof and methods for treatment of diseases |
| WO2019046167A1 (en) | 2017-08-30 | 2019-03-07 | Acadia Pharmaceuticals Inc. | PIMAVANSERIN FORMULATIONS |
| JP2018035199A (ja) * | 2017-12-07 | 2018-03-08 | 東和薬品株式会社 | シロドシンγ型結晶及びその製造方法 |
| CN111201218A (zh) * | 2017-12-22 | 2020-05-26 | 广东东阳光药业有限公司 | 一种哌马色林半酒石酸盐的新晶型及其制备方法 |
| IT201800003736A1 (it) | 2018-03-19 | 2019-09-19 | Lundbeck Pharmaceuticals Italy S P A | Processo per la produzione di Pimavanserin |
| IT201800009690A1 (it) | 2018-10-23 | 2020-04-23 | Lundbeck Pharmaceuticals Italy Spa | Processo per la produzione di pimavanserina |
| US20220016101A1 (en) | 2018-10-30 | 2022-01-20 | Acadia Pharmaceuticals Inc. | Methods of treating depression, anxiety and sexual dysfunction using the compound pimavanserin |
| CN111320568B (zh) * | 2018-12-15 | 2021-12-07 | 浙江京新药业股份有限公司 | 一种匹莫范色林的新晶型及其制备方法 |
| PL3741744T3 (pl) * | 2019-05-22 | 2022-04-25 | Zakłady Farmaceutyczne "Polpharma" S.A. | Farmaceutyczny produkt pośredni do wytwarzania pimawanseryny |
| WO2021016369A1 (en) | 2019-07-22 | 2021-01-28 | Acadia Pharmaceuticals Inc. | Pimavanserin for trating schizophrenia or for treating psychosis secondary to neurodegenerative disorders or depressive disorder |
| US20220323429A1 (en) | 2019-08-15 | 2022-10-13 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating neurodegenerative diseases |
| AU2020378061A1 (en) | 2019-11-08 | 2022-05-26 | Chemocentryx, Inc. | Free base crystalline form of a complement component C5a receptor |
| AU2020380367B2 (en) | 2019-11-08 | 2026-06-04 | Chemocentryx, Inc. | Salt forms of a complement component C5a receptor |
| KR20220098754A (ko) | 2019-11-08 | 2022-07-12 | 케모센트릭스, 인크. | 보체 성분 C5a 수용체의 비정질 형태 |
| CN113214231B (zh) * | 2020-01-21 | 2022-04-08 | 瀚远医药有限公司 | 5ht2a受体拮抗剂及其医疗应用 |
| WO2022094230A1 (en) | 2020-11-02 | 2022-05-05 | Acadia Pharmaceuticals Inc. | Compounds for treating psychosis or depression |
| CN112920108A (zh) * | 2021-01-29 | 2021-06-08 | 北京诺康达医药科技股份有限公司 | 酒石酸匹莫范色林晶型a的制备方法 |
| CN114874103B (zh) * | 2022-05-11 | 2024-09-06 | 合肥立方制药股份有限公司 | 一种匹莫范色林中间体4-异丁氧基苄胺的连续合成方法 |
| JP7406285B1 (ja) | 2023-03-09 | 2023-12-27 | 国立大学法人島根大学 | ビリルビン誘発性神経機能障害、黄疸を伴う精神疾患、又はビリルビンｕｄｐ－グルクロン酸転移酵素遺伝子変異に起因する精神疾患を治療、予防又は管理するための医薬組成物 |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE794333A (fr) | 1972-01-20 | 1973-07-19 | Wyeth John & Brother Ltd | Composes heterocycliques azotes therapeutiques |
| GB1507462A (en) | 1974-03-21 | 1978-04-12 | Gallardo Antonio Sa | N-heterocyclic substituted benzamides methods for their preparation and compositions containing them |
| US3983234A (en) | 1974-07-04 | 1976-09-28 | Sandoz Ltd. | Treatment of dyskinesias |
| GB1586468A (en) | 1976-10-29 | 1981-03-18 | Anphar Sa | Piperidine derivatives |
| CA1140119A (en) | 1978-04-03 | 1983-01-25 | Joseph Torremans | N-heterocyclyl-4-piperidinamines |
| US4255432A (en) | 1979-09-06 | 1981-03-10 | Syntex (U.S.A.) Inc. | 8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof |
| US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| US4353900A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
| US4353901A (en) | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
| GB8527052D0 (en) | 1985-11-02 | 1985-12-04 | Beecham Group Plc | Compounds |
| GB8621892D0 (en) | 1986-09-11 | 1986-10-15 | Lundbeck & Co As H | Organic compound |
| FR2642069B1 (fr) | 1989-01-20 | 1991-04-12 | Rhone Poulenc Sante | Nouveaux derives du benzopyranne, leur preparation et les compositions pharmaceutiques qui les contiennent |
| US5214055A (en) | 1990-05-18 | 1993-05-25 | Adir Et Compagnie | Aminopiperidine 4-oxo-4H-chromen-2-yl compounds |
| US5216165A (en) | 1990-10-03 | 1993-06-01 | American Home Products Corporation | N-substituted aminoquinolines as analgesic agents |
| IT1252227B (it) | 1991-12-17 | 1995-06-05 | Ciba Geigy Spa | Composti tetrametilpiperidinici atti all'impiego come stabilizzanti per materiali organici |
| US5595872A (en) | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| CA2123728A1 (en) | 1993-05-21 | 1994-11-22 | Noriyoshi Sueda | Urea derivatives and their use as acat inhibitors |
| WO1994027967A1 (en) | 1993-05-26 | 1994-12-08 | Smithkline Beecham Laboratoires Pharmaceutiques | Novel compounds |
| IL110298A (en) | 1993-07-13 | 1999-04-11 | Brann Mark Robert | Identification of ligands by selective amplification of cells transfected with receptors |
| DE4404183A1 (de) | 1994-02-10 | 1995-08-17 | Merck Patent Gmbh | 4-Amino-1-piperidylbenzoylguanidine |
| US5795894A (en) | 1995-05-02 | 1998-08-18 | Schering Corporation | Piperazino derivatives as neurokinn antagonists |
| BR9610277A (pt) | 1995-08-31 | 1999-07-06 | Schering Corp | Derivados de piperazino como antagonistas de neurowuinina |
| WO1997011940A1 (en) | 1995-09-29 | 1997-04-03 | Eli Lilly And Company | Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation |
| EP0944388A4 (en) | 1996-04-03 | 2001-08-16 | Merck & Co Inc | INHIBITORS OF FARNESYL PROTEIN TRANSFERASE |
| JP2002503207A (ja) | 1996-04-17 | 2002-01-29 | デュポン ファーマシューティカルズ カンパニー | Ｘａ因子阻害剤としてのＮ―（アミジノフェニル）―Ｎ’―（置換）―３Ｈ―２，４―ベンゾジアゼピン―３―オン誘導体 |
| US5869488A (en) | 1996-05-01 | 1999-02-09 | Schering Corporation | Piperazino derivatives as neurokinin antagonists |
| US5877173A (en) | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
| DE59711622D1 (de) | 1996-09-10 | 2004-06-17 | Boehringer Ingelheim Pharma | Abgewandelte aminosäuren, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| DE19643331A1 (de) | 1996-10-21 | 1998-04-23 | Thomae Gmbh Dr K | 1-(4-Piperidinyl)-piperidinylene, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
| US6057338A (en) | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| TR199902752T2 (xx) | 1997-05-08 | 2000-06-21 | Smithkline Beecham Corporation | Proteaz inhibit�rleri. |
| AU736542B2 (en) * | 1997-06-27 | 2001-08-02 | Merck Sharp & Dohme Limited | Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents |
| US20020163987A1 (en) * | 1997-12-12 | 2002-11-07 | British Nuclear Fuels Plc | Monitoring a sample containing a neutron source |
| US6107324A (en) | 1998-04-14 | 2000-08-22 | Arena Pharmaceuticals Inc. | 5-HT2A receptor inverse agonists |
| US6140509A (en) | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
| US6358698B1 (en) | 1998-10-07 | 2002-03-19 | Acadia Pharmacueticals Inc. | Methods of identifying inverse agonists of the serotonin 2A receptor |
| CA2315050C (en) | 1998-10-16 | 2009-02-03 | Suntory Limited | Aminophenoxyacetic acid derivatives and pharmaceutical composition containing thereof |
| US6150393A (en) | 1998-12-18 | 2000-11-21 | Arena Pharmaceuticals, Inc. | Small molecule modulators of non-endogenous, constitutively activated human serotonin receptors |
| EP1013276A1 (en) | 1998-12-23 | 2000-06-28 | Pfizer Inc. | Aminoazacycloalkanes as CCR5 modulators |
| CA2367112A1 (en) | 1999-03-24 | 2000-09-28 | The Regents Of The University Of California | Methods for treating neurodegenerative disorders using aspartyl protease inhibitors |
| US6399619B1 (en) | 1999-04-06 | 2002-06-04 | Merck & Co., Inc. | Pyrrolidine modulators of chemokine receptor activity |
| AU4537900A (en) | 1999-05-17 | 2000-12-05 | Agouron Pharmaceuticals, Inc. | Glucagon antagonists/inverse agonists |
| US20050148018A1 (en) | 1999-10-07 | 2005-07-07 | David Weiner | Methods of identifying inverse agonists of the serotonin 2A receptor |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| US7022698B2 (en) | 1999-12-28 | 2006-04-04 | U & I Pharmaceuticals, Ltd. | Pharmaceutical compositions containing new polymorphic forms of olanzapine and uses thereof |
| KR100879647B1 (ko) | 2000-03-06 | 2009-01-20 | 아카디아 파마슈티칼스 인코포레이티드 | 세로토닌 관련 질병의 치료에 사용되는 아자시클릭 화합물 |
| GB0011838D0 (en) | 2000-05-17 | 2000-07-05 | Astrazeneca Ab | Chemical compounds |
| GB0108099D0 (en) | 2001-03-30 | 2001-05-23 | Hoffmann La Roche | Aminopiperidine derivatives |
| DE60231209D1 (de) * | 2001-06-05 | 2009-04-02 | Toyo Boseki | Antithrombotische zusammensetzungen und diese enthaltende medizinische instrumente |
| NZ533567A (en) | 2001-12-28 | 2007-06-29 | Acadia Pharm Inc | Spiroazacyclic compounds as monoamine receptor for modulating 5-HT2A receptor-mediated events |
| KR20040075353A (ko) | 2002-01-17 | 2004-08-27 | 제너럴 일렉트릭 캄파니 | 양이온성 개시제로서 약하게 배위된 이미다졸리딘음이온을 포함하는 오늄 염 |
| EP1509505A2 (en) | 2002-01-23 | 2005-03-02 | Arena Pharmaceuticals, Inc. | SMALL MOLECULE MODULATORS OF THE 5−HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO |
| UY27668A1 (es) | 2002-02-20 | 2003-10-31 | Pfizer Prod Inc | Composición de ziprasidona y controles sintéticos |
| GB0208279D0 (en) | 2002-04-10 | 2002-05-22 | Glaxo Group Ltd | Novel compounds |
| JP2005533813A (ja) | 2002-06-24 | 2005-11-10 | アカディア ファーマシューティカルズ，インコーポレーテッド | セロトニン受容体作用物質としてのｎ−置換ピペリジン誘導体 |
| US7253186B2 (en) | 2002-06-24 | 2007-08-07 | Carl-Magnus Andersson | N-substituted piperidine derivatives as serotonin receptor agents |
| US7538222B2 (en) | 2002-06-24 | 2009-05-26 | Acadia Pharmaceuticals, Inc. | N-substituted piperidine derivatives as serotonin receptor agents |
| WO2004009549A2 (en) | 2002-07-18 | 2004-01-29 | Actelion Pharmaceuticals Ltd | Piperidines useful for the treatment of central nervous system disorders |
| WO2004039322A2 (en) | 2002-10-29 | 2004-05-13 | Miicro, Inc. | Novel combination therapy for schizophrenia focused on improved cognition: 5-ht-2a/d2 blockade with adjunctive blockade of prefrontal da reuptake |
| ATE407117T1 (de) | 2003-01-16 | 2008-09-15 | Acadia Pharm Inc | Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen |
| WO2004064753A2 (en) * | 2003-01-23 | 2004-08-05 | Acadia Pharmaceuticals Inc | Use of n-desmethylclozapine to treat human neuropsychiatric disease |
| PT1594840E (pt) | 2003-02-17 | 2007-01-31 | Hoffmann La Roche | Derivados de piperidina-benzenossulfonamida |
| US7628762B2 (en) | 2003-03-19 | 2009-12-08 | Suros Surgical Systems, Inc. | Adapter assembly for stereotactic biopsy |
| BRPI0417749A (pt) | 2003-12-22 | 2007-04-10 | Acadia Pharm Inc | composto, método de sintese de composto, bibliotecas combinatórias, composições farmacêuticas e métodos de tratamento de disfunções neuropsiquiátricas |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| US7820695B2 (en) * | 2004-05-21 | 2010-10-26 | Acadia Pharmaceuticals, Inc. | Selective serotonin receptor inverse agonists as therapeutics for disease |
| CN101031548B (zh) * | 2004-09-27 | 2011-04-06 | 阿卡蒂亚药品公司 | N-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n'-(4-(2-甲基丙氧基)-苯基甲基)脲的盐及其制备 |
| US7790899B2 (en) * | 2004-09-27 | 2010-09-07 | Acadia Pharmaceuticals, Inc. | Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms |
-
2005
- 2005-09-26 CN CN2005800326490A patent/CN101031548B/zh not_active Expired - Lifetime
- 2005-09-26 RU RU2007115921/04A patent/RU2387643C2/ru active
- 2005-09-26 AU AU2005289635A patent/AU2005289635A1/en not_active Abandoned
- 2005-09-26 KR KR1020077009395A patent/KR20070083800A/ko not_active Withdrawn
- 2005-09-26 PL PL05805643T patent/PL1794126T3/pl unknown
- 2005-09-26 AU AU2005289444A patent/AU2005289444B2/en not_active Expired
- 2005-09-26 WO PCT/US2005/034813 patent/WO2006037043A1/en not_active Ceased
- 2005-09-26 BR BRPI0516063-4A patent/BRPI0516063A/pt not_active Application Discontinuation
- 2005-09-26 RU RU2007115886/04A patent/RU2417986C2/ru active
- 2005-09-26 SG SG201002293-7A patent/SG161221A1/en unknown
- 2005-09-26 ES ES05805643T patent/ES2412207T3/es active Active
- 2005-09-26 MX MX2007003433A patent/MX2007003433A/es active IP Right Grant
- 2005-09-26 JP JP2007533762A patent/JP4996467B2/ja not_active Expired - Lifetime
- 2005-09-26 DK DK05805643.3T patent/DK1794126T3/da active
- 2005-09-26 CA CA2580136A patent/CA2580136C/en not_active Expired - Lifetime
- 2005-09-26 EP EP10180395.5A patent/EP2289879B1/en not_active Expired - Lifetime
- 2005-09-26 ES ES10180395.5T patent/ES2530258T3/es active Active
- 2005-09-26 SG SG200907436-0A patent/SG157378A1/en unknown
- 2005-09-26 CN CN201110039289.4A patent/CN102153505B/zh not_active Expired - Lifetime
- 2005-09-26 US US11/235,381 patent/US7868176B2/en active Active
- 2005-09-26 JP JP2007533699A patent/JP5154227B2/ja not_active Expired - Lifetime
- 2005-09-26 CA CA002580129A patent/CA2580129A1/en not_active Abandoned
- 2005-09-26 NZ NZ553702A patent/NZ553702A/en not_active IP Right Cessation
- 2005-09-26 US US11/235,558 patent/US7732615B2/en active Active
- 2005-09-26 KR KR1020077009394A patent/KR101260036B1/ko not_active Expired - Lifetime
- 2005-09-26 CN CN2005800326503A patent/CN101035759B/zh not_active Expired - Lifetime
- 2005-09-26 WO PCT/US2005/034376 patent/WO2006036874A1/en not_active Ceased
- 2005-09-26 MX MX2007003403A patent/MX2007003403A/es not_active Application Discontinuation
- 2005-09-26 EP EP05801891A patent/EP1794125A1/en not_active Withdrawn
- 2005-09-26 PL PL10180395T patent/PL2289879T3/pl unknown
- 2005-09-26 EP EP05805643A patent/EP1794126B1/en not_active Expired - Lifetime
-
2006
- 2006-05-03 US US11/417,447 patent/US20060205780A1/en not_active Abandoned
- 2006-05-03 US US11/418,341 patent/US20060205781A1/en not_active Abandoned
-
2007
- 2007-03-20 ZA ZA200702349A patent/ZA200702349B/xx unknown
- 2007-03-20 ZA ZA200702345A patent/ZA200702345B/xx unknown
-
2010
- 2010-01-29 ZA ZA201000714A patent/ZA201000714B/en unknown
- 2010-06-07 US US12/795,547 patent/US7923564B2/en not_active Expired - Lifetime
-
2011
- 2011-04-06 US US13/081,427 patent/US8236960B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005503386A5 (enExample) | ||
| RU2007115886A (ru) | Синтез n-(4-фторбензил)-n-(1-метилпиперидин-4-ил)-n`-(2-метилпропилокси)фенилметил)карбамида, а также его тартрата и кристаллических форм | |
| TWI632131B (zh) | 用於製備前列腺素醯胺之新穎方法 | |
| JP5305248B2 (ja) | 新規ナテグリニド結晶 | |
| JP2009035547A (ja) | リモナバントの結晶多形の製造方法 | |
| JP2009535340A5 (enExample) | ||
| JP2022551525A5 (enExample) | ||
| JP2012533550A5 (enExample) | ||
| JP2005509025A5 (enExample) | ||
| JP2022540922A5 (enExample) | ||
| JP2004513106A (ja) | 塩酸ベンラファキシンの結晶形 | |
| JP2024540922A5 (enExample) | ||
| JP2024505063A5 (enExample) | ||
| TWI727517B (zh) | 貝前列素-314d晶體及其製備方法 | |
| JP5160892B2 (ja) | （３−シアノ−１ｈ−インドール−７−イル）−［４−（４−フルオロフェネチル）ピペラジン−１−イル］メタノン塩酸塩の新規な結晶形 | |
| KR102877903B1 (ko) | 파소라세탐의 고체 형태 | |
| TW201041855A (en) | New process for preparing | |
| JP6307634B2 (ja) | アリサルタン・イソプロキシル結晶、その製造方法及び該結晶を含む医薬組成物 | |
| JP2914414B2 (ja) | 薬 剤 | |
| TWI781345B (zh) | Ｂａｒｉｃｉｔｉｎｉｂ的結晶型與其製備方法 | |
| JP2020517674A (ja) | ボルチオキセチンＨＢｒ α型を製造するための方法 | |
| JP6577938B2 (ja) | セフジトレンピボキシルの新規結晶形態およびその製造方法 | |
| JP2026509733A (ja) | ピペリジノ―ジヒドロチエノピリミジンスルホキシドの新規多形 | |
| KR100806673B1 (ko) | 결정상 시부트라민 프리베이스의 제조방법 | |
| HK40120719A (en) | Crystalline form of lanifibranor |